Advertisement
  • Loading metrics

Endomyocardial Fibrosis: Still a Mystery after 60 Years

  • Gene Bukhman ,

    gbukhman@partners.org

    Affiliation Division of Social Medicine and Health Inequalities, Brigham and Women's Hospital, Boston, Massachusetts, United States of America

  • John Ziegler,

    Affiliation Cancer Risk Program, University of California San Francisco, San Francisco, California, United States of America

  • Eldryd Parry

    Affiliation Clinical Research Unit, London School of Hygiene & Tropical Medicine, London, United Kingdom

Endomyocardial Fibrosis: Still a Mystery after 60 Years

  • Gene Bukhman, 
  • John Ziegler, 
  • Eldryd Parry
PLOS
x

Abstract

The pathologist Jack N. P. Davies identified endomyocardial fibrosis in Uganda in 1947. Since that time, reports of this restrictive cardiomyopathy have come from other parts of tropical Africa, South Asia, and South America. In Kampala, the disease accounts for 20% of heart disease patients referred for echocardiography. We conducted a systematic review of research on the epidemiology and etiology of endomyocardial fibrosis. We relied primarily on articles in the MEDLINE database with either “endomyocardial fibrosis” or “endomyocardial sclerosis” in the title. The volume of publications on endomyocardial fibrosis has declined since the 1980s. Despite several hypotheses regarding cause, no account of the etiology of this disease has yet fully explained its unique geographical distribution.

September 2007 will mark the 60th anniversary of the description of endomyocardial fibrosis (EMF) in Uganda by the pathologist Jack N. P. Davies [1]. Observed by Arthur Williams as early as 1938, Davies and his colleagues at Makerere University delineated the clinico-pathologic features of this new restrictive cardiomyopathy, still called Davies disease by some [2],[3],[4]. Although virtually unknown outside of the tropics, cases of EMF continue to surface from parts of equatorial Asia and South America where the disease afflicts impoverished children and young adults [5]. The highest prevalence of this condition likely remains, however, in regions of sub-Saharan Africa. As a rough estimate, the burden of EMF may well compare in scope to Chagas cardiomyopathy [6].

Subendocardial fibrosis of the apices and inflow tracts of the right ventricle, left ventricle, or both defines the disease [7],[8]. This restrictive scarring prevents ventricular filling, and tethering of the papillary muscles leads to valvular regurgitation (Figure 1; Video S1). A review of autopsies in Uganda between 1959 and 1969 emphasized the poor prognosis of this condition, with an average survival of 2 y after symptom onset [9]. Later series from Brazil and India found more variability in the course of medically treated patients and echoed findings from southern Nigeria of both acute and chronic forms of the disease [10],[11],[12]. The advent of surgical resection and valvular replacement during the 1970s promised 10-y survival rates as high as 68% for selected patients, but at the price of high peri-operative mortality [13],[14],[15],[16],[17]. Unfortunately, EMF has most affected those regions least equipped with cardiovascular surgery.

thumbnail
Figure 1. Top, echocardiogram in a 25-y-old man with predominantly right ventricular EMF from eastern Rwanda.

Apical four-chamber view. Note the marked dilatation of the right atrium. RV = right ventricle, RA = right atrium, LV = left ventricle, LA = left atrium. Bottom, massive ascites in the same patient.

https://doi.org/10.1371/journal.pntd.0000097.g001

The question of whether all cases of EMF have the same underlying cause still ranks as one of the great mysteries in cardiology. Does the pathogenesis of this disease result from a single process? Or does EMF represent a common pathway for diverse insults such as those that lead to dilated cardiomyopathies?

Davies himself, who died in 1998 at the age of 83, believed to the end that EMF had a unifying explanation [18]. He thought the clue perhaps lay in the similarity between the heart lesion in EMF and the endocarditis parietalis fibroplastica that Wilhelm Löffler and others had described in Europe in the setting of hypereosinophilic syndromes [19],[20]. The eosinophil hypothesis—dominant though still not well tested—has failed to convince critics who point to other plausible alternatives [21],[22],[23],[24]. In fact, none of the etiologic categories first mentioned by Williams, Ball, and Davies in 1954 have left the table of possible causes (Table 1) [25].

Despite uncertainty as to the cause of EMF, the volume of publications on the subject has declined during the past decade (Figure 2). In an effort to rekindle interest in this neglected disease, we have undertaken a systematic review of research on this condition. We have based this review primarily on articles in the MEDLINE database published between January 1, 1950 and January 1, 2007 with either “endomyocardial fibrosis” or “endomyocardial sclerosis” in the title. We limited this search to articles in English, French, or Spanish and did not search other databases. We consulted additional papers and books referenced through this search strategy, and have cited those most focused on epidemiology and etiology.

thumbnail
Figure 2. Number of publications in MEDLINE between 1950 and 2006 with either “endomyocardial fibrosis” or “endomyocardial sclerosis” in the title.

https://doi.org/10.1371/journal.pntd.0000097.g002

Epidemiology

The clinical manifestations of EMF of either ventricle overlap with other conditions that cause heart failure or ascites. For this reason, a conclusive diagnosis of EMF depends on imaging or surgical visualization of the heart during life, or on autopsy after death [26],[27],[28].

Since the first descriptions of EMF at autopsy in West and East Africans in the late 1940s, over 2,400 cases of the disease have been reported throughout the world [1],[29]. Half of these cases have come from sub-Saharan Africa, and a quarter have come from Uganda alone. Connor and colleagues have questioned the relationship between Ugandan EMF and the West African disease [3]. Other regions with large series include Brazil, Côte d'Ivoire, southern Nigeria, coastal Mozambique, and Kerala State in India (Figure 3). Reporting bias skews this distribution, and in the absence of population-based studies, worldwide prevalence can only be estimated.

thumbnail
Figure 3. Distribution by country of published cases of endomyocardial fibrosis between 1950 and 2006.

Includes only those cases diagnosed at autopsy, or confirmed by surgery or cardiac imaging. Within-country variation depicted for Brazil, China, India, Mozambique, and Nigeria.

https://doi.org/10.1371/journal.pntd.0000097.g003

The frequency of EMF cases in Uganda has a bimodal peak at age 10 and age 30 [30]. Childhood EMF in this country affects boys and girls equally, while adult EMF affects women twice as often as men [30],[31]. In Nigeria, some studies have found a two to one male preponderance, while others have not shown any difference between the sexes [32].

The majority of EMF cases have come from low-lying, humid parts of tropical countries (Table 2). In East Africa, Uganda has a striking burden of EMF in contrast with Kenya and the Ethiopian highlands. In Tanzania and Mozambique, cases have clustered along the coastal forest [33],[34],[35]. Despite the frequency of EMF in the areas around the southern cities of Ibadan and Enugu in Nigeria, a review of cardiovascular admissions to a referral center in Zaria's northern savanna during the 1970s found no patients with this disease [36],[37],[38],[39]. In India, Kerala's tropical rain forest has generated one of the largest case series in the world, while other parts of the country have reported relatively few cases. In China, the largest number of case reports has also come from the southern province of Guangxi [40]. In South America, patients with EMF have come from Brazil and Columbia rather than Peru or Ecuador.

thumbnail
Table 2. Prevalence of EMF in Africa, Latin America, South Asia, China, and the Middle East.

https://doi.org/10.1371/journal.pntd.0000097.t002

Etiology

Theories about the etiology of EMF have tried to explain the condition's unusual geography and pathology. The apparent concentration of EMF in the tropics has led to a search for infectious or nutritional causes. In particular, the similarity of EMF lesions to those in Löffler endocarditis and carcinoid heart disease has suggested a connection with serotonin or eosinophil toxicity.

Unfortunately, research on EMF peaked prior to the diffusion of echocardiography in the much of the tropics [28],[41],[42],[43],[44]. The lack of non-invasive imaging restricted studies to small autopsy or angiocardiographic series [45]. Descriptions of the clinical progression of the disease suffered from lack of diagnostic confirmation as well [12],[46]. Expansion of echocardiographic referral centers and the development of a sub-Saharan heart failure registry will do much to clarify the epidemiology of EMF in this region [47].

At present, only a few investigators have tested the proposed causes of EMF. Early enthusiasm for the role of serotonin in a plantain-based diet waned by the early 1970s [48],[49],[50]. Encouraged at first by the demonstration of high 5-hydroxyindole-acetic acid (5-HIAA) levels in the urine of West and East Africans, this work culminated when McKinney and Crawford fed plantains to guinea pigs, rats, and Patus monkeys [49],[51],[52],[53],[54]. They could not reproduce typical EMF lesions. With the finding that serum 5-hydroxytryptamine (5-HT) levels failed to rise in EMF patients fed a diet of plantains in Nigeria, investigation on this hypothesis ceased [55].

The eosinophil hypothesis gained prominence in the 1960s with reports of eosinophilic endomyocardial disease among European visitors to tropical regions [56],[57],[58],[59],[60],[61]. At the same time, Ive and Brockington in Nigeria found filariasis (onchocerciasis or loiasis) rates approaching 100% among 42 patients with angiographic EMF compared with 44% of 115 controls (p<0.001) [62],[63]. The suggestion that helminth-induced eosinophilia precipitated a tropical variant of the eosinophilic heart disease known as Löffler's found support in later accounts of helminth-associated EMF in natives and visitors to sub-Saharan Africa [64],[65].

The case for the equivalence of end-stage Löffler's and EMF rests on two formal evaluations [31]. The first study, published by Brockington and Olsen in 1975, compared the histology of 30 cases of Löffler's with 32 cases of EMF drawn from Uganda, Nigeria, and Brazil [66]. On the basis of this work, Olsen proposed three stages of Löffler's [67]. In patients with 1 to 2 mo of symptoms prior to autopsy, an eosinophilic myocarditis marked the necrotic stage. Those who died after 10 mo of symptoms had endocardial thickening and thrombosis rather than myocarditis. Among those 16 Löffler patients with more than 2 y of symptoms prior to autopsy, Olsen described a final fibrotic stage that he found identical to EMF. In a clinical and echocardiographic study published in 1983, Davies and colleagues confirmed these findings [31]. In 11 patients from the United Kingdom on the one hand, and 47 patients from India and Brazil on the other, they found no significant differences between fibrotic stage Löffler's and EMF.

Endomyocardial biopsies have failed, however, to demonstrate an eosinophilic myocarditis in EMF. In a series of 49 patients with EMF who underwent biopsies in Uganda, none had tissue eosinophilia despite early presentation in several cases [68]. Attempts to reproduce the Nigerian filariasis findings in other small studies have also failed to show a difference in prevalence of parasite exposure or eosinophilia between EMF cases and controls [69],[70]. In Uganda, one study found that 60% of echocardiographic cases had at least mild eosinophilia compared with 10% of controls (odds ratio 4.6) [30]. Another small study from this country has not shown a difference in rates of eosinophilia [24].

More recently, Andy and colleagues in Nigeria have argued in favor of the helminth-driven eosinophilia hypothesis. In a fascinating study weakened somewhat by lack of diagnostic confirmation, the investigators found an inverse relationship between eosinophil levels and duration of EMF disease [46]. In 89 cases of EMF, only 20% of patients who presented within 6 mo of symptom onset had normal eosinophil concentrations.

Aside from inconsistencies between the pathology of Löffler's and EMF, the mismatch between the geography of EMF and the ubiquity of parasite-induced eosinophilia calls into question the relationship between these entities [71]. Despite the burden of tropical pulmonary eosinophilia on the basis of lymphatic filariasis in Southeast Asia, for example, these countries have not reported much EMF. Rural Haiti has not reported any EMF cases, despite an active echocardiography service at Deschapelles in the Artibonite Valley [72]. Ecological research of disease causation leaves much room for confounding.

Some have sought a more direct connection between EMF and malarial infection. EMF cases in Uganda have disproportionately come from Rwanda-Burundi immigrant families [73]. While the poverty of these migrants confounds association, others have suggested that movement from zones of lower to higher malaria prevalence might hold the key. Following van der Geld, during the late 1960s Shaper and colleagues found increased levels of anti-malarial and anti-heart antibodies among these migrants and EMF cases in particular [74],[75],[76]. Ziegler, Patel, and colleagues identified a series of familial cases of EMF among Rwanda-Burundi migrants who had massive splenomegaly, a condition associated with malaria-induced immune hyper-reactivity [68],[77]. While the prevalence of plasmodial species does not match the geographic distribution of EMF, these findings point to changes in immunity as a possible pathway from malaria to endocardial disease.

In a separate line of inquiry in Kerala State, India, the high prevalence of EMF along a coastal zone free of filariasis has led investigators to pursue a geochemical hypothesis. Valiathan and Kartha have speculated that cerium or thorium present in monazite deposits may explain regional variation in EMF prevalence in this region [23],[78]. No empirical studies have yet come forward to support this theory.

Investigations into nutritional factors in EMF have focused on a possible connection with cassava toxicity. A case-control study from Uganda has shown an association between EMF and markers of poverty such as farming, lack of shoes, and cassava-based diets with little animal protein [30]. Some have suggested that cerium-mediated cassava toxicity in the setting of protein deficiency may play a role in the pathogenesis of EMF [79]. Despite the known role of cyanogens from improperly processed cassava in konzo, an upper-motor neuron disease reported from Central and East Africa, cardiac manifestations have not had a part in these outbreaks [80].

Future Directions

Given the difficulty of cardiovascular research in resource-poor settings, the supply of theories about EMF has exceeded the reach of investigation. The disease accounts for a striking proportion of heart failure in some regions. The dissemination of echocardiography in tropical countries should facilitate prospective studies that clarify case definition and generate new insights into the mechanisms of heart failure in sub-Saharan Africa. At the same time, molecular techniques could bring new life to old ideas.

The fusion protein FIP1L1-PDGFRα, a constitutively activated tyrosine kinase found in as many as half of those with the idiopathic hypereosinophilic syndrome, has emerged as a therapeutic target for imatinib [81]. The prevalence of FIP1L1-PDGFRα among those with EMF could give another important clue about the etiology and treatment of this disease.

Studies that measure levels of markers, such as C-reactive peptide or inflammatory cytokines such as tumor necrosis factor α, could help explore the role of inflammation in EMF and suggest therapeutic strategies in early forms of the disease [82].

Echocardiographic studies of patients with hyper-reactive malarial splenomegaly could shed light on the prevalence of early endocardial disorders in this population.

The recent finding that serotonin acts as a chemotactic factor for eosinophils may reignite inquiries into the role of this pathway in EMF [83]. Zanettini and colleagues have found that some anti-Parkinson medications induce valvular fibrosis via their action on 5HT2B receptors [84]. Could polymorphisms in this receptor influence susceptibility to EMF in the presence of intermittent eosinophilia?

Box 1. Key Learning Points

  • Endomyocardial fibrosis, a restrictive cardiomyopathy, has a high prevalence in tropical regions of sub-Saharan Africa, South Asia, and South America.
  • We found no conclusive evidence that parasite-induced eosinophilia explains the pathogenesis of this condition, but the etiological role of eosinophils remains an open question.
  • Uncertainty continues about the distribution and causes of the disease.

Box 2. Five Key Papers in the Field

  1. Davies JNP (1948) Endomyocardial fibrosis in Uganda. East Afr Med J 25: 10–16.
  2. Parry EH, Abrahams DG (1965) The natural history of endomyocardial fibrosis. Q J Med 34: 383–408.
  3. Connor DH, Somers K, Hutt MS, Manion WC, D'Arbela PG (1967) Endomyocardial fibrosis in Uganda (Davies' disease). 1. An epidemiologic, clinical, and pathologic study. Am Heart J 74: 687–709.
  4. Andy JJ, Ogunowo PO, Akpan NA, Odigwe CO, Ekanem IA, et al. (1998) Helminth associated hypereosinophilia and tropical endomyocardial fibrosis (EMF) in Nigeria. Acta Trop 69: 127–140.
  5. Rutakingirwa M, Ziegler JL, Newton R, Freers J (1999) Poverty and eosinophilia are risk factors for endomyocardial fibrosis (EMF) in Uganda. Trop Med Int Health 4: 229–235.

Supporting Information

Video S1.

Echocardiogram in a 25 year-old man with predominantly right ventricular EMF from eastern Rwanda. Apical four-chamber view. Note the marked dilatation of the right atrium.

https://doi.org/10.1371/journal.pntd.0000097.s001

(2.01 MB CDR)

Acknowledgments

We would like to thank Dan Connor, Kris Somers, and three anonymous reviewers for their comments on an earlier version of this paper. We would also like to thank Peter Weller for his advice on eosinophilic disease in the tropics.

Author Contributions

Conceived and designed the experiments: GB JZ EP. Analyzed the data: GB JZ EP. Wrote the paper: GB JZ EP. Initiated this review and wrote the first draft: GB Contributed substantially to the conception and revision of the paper: JZ EP.

References

  1. 1. Davies JNP (1948) Endomyocardial fibrosis in Uganda. East Afr Med J 25: 10–16.JNP Davies1948Endomyocardial fibrosis in Uganda.East Afr Med J251016
  2. 2. Ball JD, Williams AW, Davies JN (1954) Endomyocardial fibrosis. Lancet 266: 1049–1054.JD BallAW WilliamsJN Davies1954Endomyocardial fibrosis.Lancet26610491054
  3. 3. Connor DH, Somers K, Hutt MS, Manion WC, D'Arbela PG (1967) Endomyocardial fibrosis in Uganda (Davies' disease). 1. An epidemiologic, clinical, and pathologic study. Am Heart J 74: 687–709.DH ConnorK. SomersMS HuttWC ManionPG D'Arbela1967Endomyocardial fibrosis in Uganda (Davies' disease). 1. An epidemiologic, clinical, and pathologic study.Am Heart J74687709
  4. 4. Williams A (1938) Heart disease in the native population of Uganda. East African Medical Journal 15: 279.A. Williams1938Heart disease in the native population of Uganda.East African Medical Journal15279
  5. 5. Hutt MS (1983) Epidemiology aspects of endomyocardial fibrosis. Postgrad Med J 59: 142–146.MS Hutt1983Epidemiology aspects of endomyocardial fibrosis.Postgrad Med J59142146
  6. 6. Lopez AD, Disease Control Priorities Project (2006) Global burden of disease and risk factors. New York: Oxford University Press. AD LopezDisease Control Priorities Project2006Global burden of disease and risk factorsNew YorkOxford University Press
  7. 7. McKenna W, Nordet P, Martin I, Gyarfas I, Thiene G, et al. (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93: 841–842.W. McKennaP. NordetI. MartinI. GyarfasG. Thiene1996Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies.Circulation93841842
  8. 8. Freers J, Hakim J, Myanja-Kizza H, Parry E (2004) The heart. In: Parry E, Godfrey R, Mabey D, Gill G, editors. Principles of medicine in Africa. Cambridge: Cambridge University Press. pp. 837–886.J. FreersJ. HakimH. Myanja-KizzaE. Parry2004The heart.E. ParryR. GodfreyD. MabeyG. GillPrinciples of medicine in AfricaCambridgeCambridge University Press837886
  9. 9. D'Arbela PG, Mutazindwa T, Patel AK, Somers K (1972) Survival after first presentation with endomyocardial fibrosis. Br Heart J 34: 403–407.PG D'ArbelaT. MutazindwaAK PatelK. Somers1972Survival after first presentation with endomyocardial fibrosis.Br Heart J34403407
  10. 10. Barretto AC, da Luz PL, de Oliveira SA, Stolf NA, Mady C, et al. (1989) Determinants of survival in endomyocardial fibrosis. Circulation 80: I177–182.AC BarrettoPL da LuzSA de OliveiraNA StolfC. Mady1989Determinants of survival in endomyocardial fibrosis.Circulation80I177182
  11. 11. Gupta PN, Valiathan MS, Balakrishnan KG, Kartha CC, Ghosh MK (1989) Clinical course of endomyocardial fibrosis. Br Heart J 62: 450–454.PN GuptaMS ValiathanKG BalakrishnanCC KarthaMK Ghosh1989Clinical course of endomyocardial fibrosis.Br Heart J62450454
  12. 12. Parry EH, Abrahams DG (1965) The natural history of endomyocardial fibrosis. Q J Med 34: 383–408.EH ParryDG Abrahams1965The natural history of endomyocardial fibrosis.Q J Med34383408
  13. 13. Moraes F, Lapa C, Hazin S, Tenorio E, Gomes C, et al. (1999) Surgery for endomyocardial fibrosis revisited. Eur J Cardiothorac Surg 15: 309–312.F. MoraesC. LapaS. HazinE. TenorioC. Gomes1999Surgery for endomyocardial fibrosis revisited.Eur J Cardiothorac Surg15309312discussion 312–303. discussion 312–303.
  14. 14. Schneider U, Jenni R, Turina J, Turina M, Hess OM (1998) Long-term follow up of patients with endomyocardial fibrosis: effects of surgery. Heart 79: 362–367.U. SchneiderR. JenniJ. TurinaM. TurinaOM Hess1998Long-term follow up of patients with endomyocardial fibrosis: effects of surgery.Heart79362367
  15. 15. Metras D, Coulibaly AQ, Ouattara K (1987) Recent trends in the surgical treatment of endomyocardial fibrosis. J Cardiovasc Surg (Torino) 28: 607–613.D. MetrasAQ CoulibalyK. Ouattara1987Recent trends in the surgical treatment of endomyocardial fibrosis.J Cardiovasc Surg (Torino)28607613
  16. 16. Cherian SM, Jagannath BR, Nayar S, Cherian KM (2006) Successful reoperation after 17 years in a case of endomyocardial fibrosis. Ann Thorac Surg 82: 1115–1117.SM CherianBR JagannathS. NayarKM Cherian2006Successful reoperation after 17 years in a case of endomyocardial fibrosis.Ann Thorac Surg8211151117
  17. 17. Dubost C, Prigent C, Gerbaux A, Maurice P, Passelecq J, et al. (1983) Surgical approaches in endomyocardial disease. Postgrad Med J 59: 160–161.C. DubostC. PrigentA. GerbauxP. MauriceJ. Passelecq1983Surgical approaches in endomyocardial disease.Postgrad Med J59160161
  18. 18. Obituaries (1998) Jack Neville Phillip Davies. BMJ 317: 1662.Obituaries1998Jack Neville Phillip Davies.BMJ3171662
  19. 19. Corssmit EP, Trip MD, Durrer JD (1999) Loffler's endomyocarditis in the idiopathic hypereosinophilic syndrome. Cardiology 91: 272–276.EP CorssmitMD TripJD Durrer1999Loffler's endomyocarditis in the idiopathic hypereosinophilic syndrome.Cardiology91272276
  20. 20. Löffler W (1936) Endocarditis parietalis fibroplastica mit Bluteosinophilie. J Suisse Med 66: 817–820.W. Löffler1936Endocarditis parietalis fibroplastica mit Bluteosinophilie.J Suisse Med66817820
  21. 21. Falase AO (1985) Are eosinophils the cause of endomyocardial fibrosis in the tropics? Afr J Med Med Sci 14: 1–2.AO Falase1985Are eosinophils the cause of endomyocardial fibrosis in the tropics?Afr J Med Med Sci1412
  22. 22. Shaper AG (1993) What's new in endomyocardial fibrosis? Lancet 342: 255–256.AG Shaper1993What's new in endomyocardial fibrosis?Lancet342255256
  23. 23. Valiathan SM, Kartha CC (1990) Endomyocardial fibrosis–the possible connexion with myocardial levels of magnesium and cerium. Int J Cardiol 28: 1–5.SM ValiathanCC Kartha1990Endomyocardial fibrosis–the possible connexion with myocardial levels of magnesium and cerium.Int J Cardiol2815
  24. 24. Patel AK, D'Arbela PG, Somers K (1977) Endomyocardial fibrosis and eosinophilia. Br Heart J 39: 238–241.AK PatelPG D'ArbelaK. Somers1977Endomyocardial fibrosis and eosinophilia.Br Heart J39238241
  25. 25. Williams AW, Ball JD, Davies JN (1954) Endomyocardial fibrosis in Africa: its diagnosis, distribution and nature. Trans R Soc Trop Med Hyg 48: 290–305; discussion, 306–211.AW WilliamsJD BallJN Davies1954Endomyocardial fibrosis in Africa: its diagnosis, distribution and nature.Trans R Soc Trop Med Hyg48290305; discussion, 306–211
  26. 26. Hassan WM, Fawzy ME, Al Helaly S, Hegazy H, Malik S (2005) Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis: a 25-year experience. Chest 128: 3985–3992.WM HassanME FawzyS. Al HelalyH. HegazyS. Malik2005Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis: a 25-year experience.Chest12839853992
  27. 27. Bertrand E, Cherian G, Das S, Dubost C, Falase A, et al. (1984) Cardiomyopathies. Technical report series 697. Geneva: World Health Organization. E. BertrandG. CherianS. DasC. DubostA. Falase1984Cardiomyopathies. Technical report series 697GenevaWorld Health Organization
  28. 28. Acquatella H, Schiller NB, Puigbo JJ, Gomez-Mancebo JR, Suarez C, et al. (1983) Value of two-dimensional echocardiography in endomyocardial disease with and without eosinophilia. A clinical and pathologic study. Circulation 67: 1219–1226.H. AcquatellaNB SchillerJJ PuigboJR Gomez-ManceboC. Suarez1983Value of two-dimensional echocardiography in endomyocardial disease with and without eosinophilia. A clinical and pathologic study.Circulation6712191226
  29. 29. Bedford DE, Konstam GLS (1946) Heart failure of unknown aetilogy in Africans. Brit Heart J 8: 236.DE BedfordGLS Konstam1946Heart failure of unknown aetilogy in Africans.Brit Heart J8236
  30. 30. Rutakingirwa M, Ziegler JL, Newton R, Freers J (1999) Poverty and eosinophilia are risk factors for endomyocardial fibrosis (EMF) in Uganda. Trop Med Int Health 4: 229–235.M. RutakingirwaJL ZieglerR. NewtonJ. Freers1999Poverty and eosinophilia are risk factors for endomyocardial fibrosis (EMF) in Uganda.Trop Med Int Health4229235
  31. 31. Davies J, Spry CJ, Vijayaraghavan G, De Souza JA (1983) A comparison of the clinical and cardiological features of endomyocardial disease in temperate and tropical regions. Postgrad Med J 59: 179–185.J. DaviesCJ SpryG. VijayaraghavanJA De Souza1983A comparison of the clinical and cardiological features of endomyocardial disease in temperate and tropical regions.Postgrad Med J59179185
  32. 32. Falase AO (1983) Endomyocardial fibrosis in Africa. Postgrad Med J 59: 170–178.AO Falase1983Endomyocardial fibrosis in Africa.Postgrad Med J59170178
  33. 33. Ferreira B, Matsika-Claquin MD, Hausse-Mocumbi AO, Sidi D, Paquet C (2002) [Geographic origin of endomyocardial fibrosis treated at the central hospital of Maputo (Mozambique) between 1987 and 1999]. Bull Soc Pathol Exot 95: 276–279.B. FerreiraMD Matsika-ClaquinAO Hausse-MocumbiD. SidiC. Paquet2002[Geographic origin of endomyocardial fibrosis treated at the central hospital of Maputo (Mozambique) between 1987 and 1999].Bull Soc Pathol Exot95276279
  34. 34. Makene WJ (1970) Endomyocardial fibrosis in Tanzania (mainland). East Afr Med J 47: 91–96.WJ Makene1970Endomyocardial fibrosis in Tanzania (mainland).East Afr Med J479196
  35. 35. Rees P (1969) The occurrence and recognition of endomyocardial fibrosis of the right ventricle in coastal Tanzania. Trans R Soc Trop Med Hyg 63: 650–655.P. Rees1969The occurrence and recognition of endomyocardial fibrosis of the right ventricle in coastal Tanzania.Trans R Soc Trop Med Hyg63650655
  36. 36. Nwokolo C (1955) Endomyocardial fibrosis and other obscure cardiopathies in eastern Nigeria. West Afr Med J 4: 103–116.C. Nwokolo1955Endomyocardial fibrosis and other obscure cardiopathies in eastern Nigeria.West Afr Med J4103116
  37. 37. Ladipo GO, Froude JR, Parry EH (1977) Pattern of heart disease in adults of the Nigerian savanna: a prospective clinical study. Afr J Med Med Sci 6: 185–192.GO LadipoJR FroudeEH Parry1977Pattern of heart disease in adults of the Nigerian savanna: a prospective clinical study.Afr J Med Med Sci6185192
  38. 38. Abrahams DG (1962) Endomyocardial fibrosis of the right ventricle. Q J Med 31: 1–20.DG Abrahams1962Endomyocardial fibrosis of the right ventricle.Q J Med31120
  39. 39. Abrahams DG (1959) An unusual form of heart-disease in West Africa; its relation to endomyocardial fibrosis. Lancet 2: 111–112.DG Abrahams1959An unusual form of heart-disease in West Africa; its relation to endomyocardial fibrosis.Lancet2111112
  40. 40. Yin R (2000) Endomyocardial fibrosis in China. Chin Med Sci J 15: 55–60.R. Yin2000Endomyocardial fibrosis in China.Chin Med Sci J155560
  41. 41. Berensztein CS, Pineiro D, Marcotegui M, Brunoldi R, Blanco MV, et al. (2000) Usefulness of echocardiography and doppler echocardiography in endomyocardial fibrosis. J Am Soc Echocardiogr 13: 385–392.CS BerenszteinD. PineiroM. MarcoteguiR. BrunoldiMV Blanco2000Usefulness of echocardiography and doppler echocardiography in endomyocardial fibrosis.J Am Soc Echocardiogr13385392
  42. 42. Freers J, Mayanja-Kizza H, Rutakingirwa M, Gerwing E (1996) Endomyocardial fibrosis: why is there striking ascites with little or no peripheral oedema? Lancet 347: 197.J. FreersH. Mayanja-KizzaM. RutakingirwaE. Gerwing1996Endomyocardial fibrosis: why is there striking ascites with little or no peripheral oedema?Lancet347197
  43. 43. Vijayaraghavan G, Davies J, Sadanandan S, Spry CJ, Gibson DG, et al. (1983) Echocardiographic features of tropical endomyocardial disease in South India. Br Heart J 50: 450–459.G. VijayaraghavanJ. DaviesS. SadanandanCJ SpryDG Gibson1983Echocardiographic features of tropical endomyocardial disease in South India.Br Heart J50450459
  44. 44. Maro E, Janabi M (2004) Echocardiographic profile of endomyocardial fibrosis in Tanzania, East Africa. Cent Afr J Med 50: 91–94.E. MaroM. Janabi2004Echocardiographic profile of endomyocardial fibrosis in Tanzania, East Africa.Cent Afr J Med509194
  45. 45. Cockshott WP, Saric S, Ikeme AC (1967) Radiological findings in endomyocardial fibrosis. Circulation 35: 913–922.WP CockshottS. SaricAC Ikeme1967Radiological findings in endomyocardial fibrosis.Circulation35913922
  46. 46. Andy JJ, Ogunowo PO, Akpan NA, Odigwe CO, Ekanem IA, et al. (1998) Helminth associated hypereosinophilia and tropical endomyocardial fibrosis (EMF) in Nigeria. Acta Trop 69: 127–140.JJ AndyPO OgunowoNA AkpanCO OdigweIA Ekanem1998Helminth associated hypereosinophilia and tropical endomyocardial fibrosis (EMF) in Nigeria.Acta Trop69127140
  47. 47. Sliwa K, Damasceno A, Mayosi BM (2005) Epidemiology and etiology of cardiomyopathy in Africa. Circulation 112: 3577–3583.K. SliwaA. DamascenoBM Mayosi2005Epidemiology and etiology of cardiomyopathy in Africa.Circulation11235773583
  48. 48. Shaper AG (1967) Plantain diets, serotonin, and endomyocardial fibrosis. Am Heart J 73: 432–434.AG Shaper1967Plantain diets, serotonin, and endomyocardial fibrosis.Am Heart J73432434
  49. 49. McKinney B, Crawford MA (1965) Fibrosis in guinea pig heart produced by plantain diet. Lancet 2: 880–882.B. McKinneyMA Crawford1965Fibrosis in guinea pig heart produced by plantain diet.Lancet2880882
  50. 50. Crawford MA (1963) Endomyocardial fibrosis and carcinoidosis. A common denominator? Am Heart J 66: 273–276.MA Crawford1963Endomyocardial fibrosis and carcinoidosis. A common denominator?Am Heart J66273276
  51. 51. Crawford MA (1962) Excretion of 5-hydroxyindolylacetic acid in East Africans. Lancet 1: 352–353.MA Crawford1962Excretion of 5-hydroxyindolylacetic acid in East Africans.Lancet1352353
  52. 52. Foy JM, Parrat JR (1962) Urinary excretion of 5-hydroxyindoleacetic acid in West Africans. Lancet 1: 942–943.JM FoyJR Parrat1962Urinary excretion of 5-hydroxyindoleacetic acid in West Africans.Lancet1942943
  53. 53. McKinney B (1976) Endocardial changes produced in Patus monkeys by the ablation of cardiac lymphatics and the administration of a plantain diet. Am Heart J 91: 484–491.B. McKinney1976Endocardial changes produced in Patus monkeys by the ablation of cardiac lymphatics and the administration of a plantain diet.Am Heart J91484491
  54. 54. McKinney B (1975) Studies on the experimental production of endomyocardial fibrosis and cardiomegaly of unknown origin by dietary means. Am Heart J 90: 206–214.B. McKinney1975Studies on the experimental production of endomyocardial fibrosis and cardiomegaly of unknown origin by dietary means.Am Heart J90206214
  55. 55. Ojo GO (1970) The pathogenesis of endomyocardial fibrosis: the question of 5-hydroxytryptamine. Br Heart J 32: 671–674.GO Ojo1970The pathogenesis of endomyocardial fibrosis: the question of 5-hydroxytryptamine.Br Heart J32671674
  56. 56. Edge J (1946) Myocardial fibrosis following arsenical therapy: report of a case. Lancet 248: 675–677.J. Edge1946Myocardial fibrosis following arsenical therapy: report of a case.Lancet248675677
  57. 57. Gray IR (1951) Endocardial fibrosis. Br Heart J 13: 387–396.IR Gray1951Endocardial fibrosis.Br Heart J13387396
  58. 58. Clark GM, Valentine E, Blount SG Jr (1956) Endocardial fibrosis simulating constrictive pericarditis; report of a case with determinations of pressure in the right side of the heart and eosinophilia. N Engl J Med 254: 349–355.GM ClarkE. ValentineSG Blount Jr1956Endocardial fibrosis simulating constrictive pericarditis; report of a case with determinations of pressure in the right side of the heart and eosinophilia.N Engl J Med254349355
  59. 59. Giraud G, Latour H, Puech P, Olivier G, Hertault J (1958) Cardiopathie filarienne: etude hemodynamique. Arch Mal Coeur Vaiss 51: 546–557.G. GiraudH. LatourP. PuechG. OlivierJ. Hertault1958Cardiopathie filarienne: etude hemodynamique.Arch Mal Coeur Vaiss51546557
  60. 60. Fournier P, Voisin C, Pauchant M, Macquet V (1961) [Parietal fibroplastic endocarditis and filariasis. Clinical, hemodynamic and anatomical study.]. Lille Med 6: 42–47.P. FournierC. VoisinM. PauchantV. Macquet1961[Parietal fibroplastic endocarditis and filariasis. Clinical, hemodynamic and anatomical study.].Lille Med64247
  61. 61. Brockington IF, Olsen EG, Goodwin JF (1967) Endomyocardial fibrosis in Europeans resident in tropical Africa. Lancet 1: 583–588.IF BrockingtonEG OlsenJF Goodwin1967Endomyocardial fibrosis in Europeans resident in tropical Africa.Lancet1583588
  62. 62. Ive FA, Willis AJ, Ikeme AC, Brockington IF (1967) Endomyocardial fibrosis and filariasis. Q J Med 36: 495–516.FA IveAJ WillisAC IkemeIF Brockington1967Endomyocardial fibrosis and filariasis.Q J Med36495516
  63. 63. Ive F, Brockington I (1966) Endomyocardial fibrosis and filariasis. Lancet 69: 212.F. IveI. Brockington1966Endomyocardial fibrosis and filariasis.Lancet69212
  64. 64. Nutman TB, Miller KD, Mulligan M, Ottesen EA (1986) Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations. J Infect Dis 154: 10–18.TB NutmanKD MillerM. MulliganEA Ottesen1986Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations.J Infect Dis1541018
  65. 65. Berenguer A, Plancha E, Munoz Gil J (2003) Right ventricular endomyocardial fibrosis and microfilarial infection. Int J Cardiol 87: 287–289.A. BerenguerE. PlanchaJ. Munoz Gil2003Right ventricular endomyocardial fibrosis and microfilarial infection.Int J Cardiol87287289
  66. 66. Brockington IF, Olsen EG (1973) Löffler's endocarditis and Davies' endomyocardial fibrosis. Am Heart J 85: 308–322.IF BrockingtonEG Olsen1973Löffler's endocarditis and Davies' endomyocardial fibrosis.Am Heart J85308322
  67. 67. Olsen EG (1983) Pathological aspects of endomyocardial fibrosis. Postgrad Med J 59: 135–141.EG Olsen1983Pathological aspects of endomyocardial fibrosis.Postgrad Med J59135141
  68. 68. Patel AK, Ziegler JL, D'Arbela PG, Somers K (1971) Familial cases of endomyocardial fibrosis in Uganda. Br Med J 4: 331–334.AK PatelJL ZieglerPG D'ArbelaK. Somers1971Familial cases of endomyocardial fibrosis in Uganda.Br Med J4331334
  69. 69. Carlisle R, Ogunba EO, McFarlane H, Onayemi OA, Oyeleye VO (1972) Immunoglobulins and antibody to Loa loa in Nigerians with endomyocardial fibrosis and other heart diseases. Br Heart J 34: 678–680.R. CarlisleEO OgunbaH. McFarlaneOA OnayemiVO Oyeleye1972Immunoglobulins and antibody to Loa loa in Nigerians with endomyocardial fibrosis and other heart diseases.Br Heart J34678680
  70. 70. Urhoghide GE, Falase AO (1987) Degranulated eosinophils, eosinophil granule basic proteins and humoral factors in Nigerians with endomyocardial fibrosis. Afr J Med Med Sci 16: 133–139.GE UrhoghideAO Falase1987Degranulated eosinophils, eosinophil granule basic proteins and humoral factors in Nigerians with endomyocardial fibrosis.Afr J Med Med Sci16133139
  71. 71. Wilson ME, Weller PF (2006) Eosinophilia. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens & practice. 2nd edition. Philadelphia: Churchill Livingstone. pp. 1478–1495.ME WilsonPF Weller2006Eosinophilia.RL GuerrantDH WalkerPF WellerTropical infectious diseases: principles, pathogens & practice. 2nd editionPhiladelphiaChurchill Livingstone14781495
  72. 72. Fett JD, Christie LG, Carraway RD, Murphy JG (2005) Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 80: 1602–1606.JD FettLG ChristieRD CarrawayJG Murphy2005Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution.Mayo Clin Proc8016021606
  73. 73. Shaper AG, Coles RM (1965) The Tribal distribution of endomyocardial fibrosis in Uganda. Br Heart J 27: 121–127.AG ShaperRM Coles1965The Tribal distribution of endomyocardial fibrosis in Uganda.Br Heart J27121127
  74. 74. Shaper AG, Kaplan MH, Foster WD, Macintosh DM, Wilks NE (1967) Immunological studies in endomyocardial fibrosis and other forms of heart-disease in the tropics. Lancet 1: 598–600.AG ShaperMH KaplanWD FosterDM MacintoshNE Wilks1967Immunological studies in endomyocardial fibrosis and other forms of heart-disease in the tropics.Lancet1598600
  75. 75. Shaper AG, Kaplan MH, Mody NJ, McIntyre PA (1968) Malarial antibodies and autoantibodies to heart and other tissues in the immigrant and indigenous peoples of Uganda. Lancet 1: 1342–1346.AG ShaperMH KaplanNJ ModyPA McIntyre1968Malarial antibodies and autoantibodies to heart and other tissues in the immigrant and indigenous peoples of Uganda.Lancet113421346
  76. 76. van der Geld H, Peetoom F, Somers K, Kanyerezi BR (1966) Immunohistological and serological studies in endomyocardial fibrosis. Lancet 2: 1210–1213.H. van der GeldF. PeetoomK. SomersBR Kanyerezi1966Immunohistological and serological studies in endomyocardial fibrosis.Lancet212101213
  77. 77. Bedu-Addo G, Bates I (2002) Causes of massive tropical splenomegaly in Ghana. Lancet 360: 449–454.G. Bedu-AddoI. Bates2002Causes of massive tropical splenomegaly in Ghana.Lancet360449454
  78. 78. Kutty VR, Abraham S, Kartha CC (1996) Geographical distribution of endomyocardial fibrosis in south Kerala. Int J Epidemiol 25: 1202–1207.VR KuttyS. AbrahamCC Kartha1996Geographical distribution of endomyocardial fibrosis in south Kerala.Int J Epidemiol2512021207
  79. 79. Sezi CL (1996) Effect of protein deficient cassava diet on Cercopithecus aethiops hearts and its possible role in the aetiology and pathogenesis of endomyocardial fibrosis in man. East Afr Med J 73: S11–S16.CL Sezi1996Effect of protein deficient cassava diet on Cercopithecus aethiops hearts and its possible role in the aetiology and pathogenesis of endomyocardial fibrosis in man.East Afr Med J73S11S16
  80. 80. Tylleskar T, Banea M, Bikangi N, Cooke RD, Poulter NH, et al. (1992) Cassava cyanogens and konzo, an upper motoneuron disease found in Africa. Lancet 339: 208–211.T. TylleskarM. BaneaN. BikangiRD CookeNH Poulter1992Cassava cyanogens and konzo, an upper motoneuron disease found in Africa.Lancet339208211
  81. 81. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201–1214.J. CoolsDJ DeAngeloJ. GotlibEH StoverRD Legare2003A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.N Engl J Med34812011214
  82. 82. Sliwa K, Fett J, Elkayam U (2006) Peripartum cardiomyopathy. Lancet 368: 687–693.K. SliwaJ. FettU. Elkayam2006Peripartum cardiomyopathy.Lancet368687693
  83. 83. Boehme SA, Lio FM, Sikora L, Pandit TS, Lavrador K, et al. (2004) Cutting edge: serotonin is a chemotactic factor for eosinophils and functions additively with eotaxin. J Immunol 173: 3599–3603.SA BoehmeFM LioL. SikoraTS PanditK. Lavrador2004Cutting edge: serotonin is a chemotactic factor for eosinophils and functions additively with eotaxin.J Immunol17335993603
  84. 84. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, et al. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356: 39–46.R. ZanettiniA. AntoniniG. GattoR. GentileS. Tesei2007Valvular heart disease and the use of dopamine agonists for Parkinson's disease.N Engl J Med3563946
  85. 85. Ijaola O, Falase AO (1990) Distribution of antibodies against Coxsackie B viruses, arboviruses and Toxoplasma gondii among patients with endomyocardial fibrosis (EMF) compared with normal subjects from EMF endemic and non-endemic zones of Nigeria. Afr J Med Med Sci 19: 93–103.O. IjaolaAO Falase1990Distribution of antibodies against Coxsackie B viruses, arboviruses and Toxoplasma gondii among patients with endomyocardial fibrosis (EMF) compared with normal subjects from EMF endemic and non-endemic zones of Nigeria.Afr J Med Med Sci1993103
  86. 86. Shaper AG (1966) Endomyocardial fibrosis and rheumatic heart-disease. Lancet 1: 639–641.AG Shaper1966Endomyocardial fibrosis and rheumatic heart-disease.Lancet1639641
  87. 87. Eling WM, Jerusalem CR, Heinen-Borries UJ, Hermsen CC, van Run-van Breda JJ (1988) Is malaria involved in the pathogenesis of tropical endomyocardial fibrosis? Acta Leiden 57: 47–52.WM ElingCR JerusalemUJ Heinen-BorriesCC HermsenJJ van Run-van Breda1988Is malaria involved in the pathogenesis of tropical endomyocardial fibrosis?Acta Leiden574752
  88. 88. Shaper AG (1972) Cardiovascular disease in the tropics. II. Endomyocardial fibrosis. Br Med J 3: 743–746.AG Shaper1972Cardiovascular disease in the tropics. II. Endomyocardial fibrosis.Br Med J3743746
  89. 89. Jaiyesimi F (1982) Controversies and advances in endomyocardial fibrosis: a review. Afr J Med Med Sci 11: 37–46.F. Jaiyesimi1982Controversies and advances in endomyocardial fibrosis: a review.Afr J Med Med Sci113746
  90. 90. Brockington IF, Olsen EG (1972) Eosinophilia and endomyocardial fibrosis. Postgrad Med J 48: 740–741.IF BrockingtonEG Olsen1972Eosinophilia and endomyocardial fibrosis.Postgrad Med J48740741
  91. 91. Davies H (1990) Endomyocardial fibrosis and the tuberous diet. Int J Cardiol 29: 3–8.H. Davies1990Endomyocardial fibrosis and the tuberous diet.Int J Cardiol2938
  92. 92. Connor DH, Somers K, Hutt MS, Manion WC, D'Arbela PG (1968) Endomyocardial fibrosis in Uganda (Davies' disease). 2. An epidemiologic, clinical, and pathologic study. Am Heart J 75: 107–124.DH ConnorK. SomersMS HuttWC ManionPG D'Arbela1968Endomyocardial fibrosis in Uganda (Davies' disease). 2. An epidemiologic, clinical, and pathologic study.Am Heart J75107124
  93. 93. Abrahams DG (1962) Endomyocardial fibrosis of the right ventricle. Quart J Med 31: 1–20.DG Abrahams1962Endomyocardial fibrosis of the right ventricle.Quart J Med31120
  94. 94. Nkowolo C (1968) Correspondence. Experimental production of endomyocardial fibrosis. Lancet 272: 102.C. Nkowolo1968Correspondence. Experimental production of endomyocardial fibrosis.Lancet272102
  95. 95. Bertrand E, Renambot J, Chauvet J, Le Bras M, Lamouche P, et al. (1975) [14 cases of constrictive endocardial fibrosis (or endomyocardial fibrosis]. Arch Mal Coeur Vaiss 68: 625–635.E. BertrandJ. RenambotJ. ChauvetM. Le BrasP. Lamouche1975[14 cases of constrictive endocardial fibrosis (or endomyocardial fibrosis].Arch Mal Coeur Vaiss68625635
  96. 96. Amoah AG, Kallen C (2000) Aetiology of heart failure as seen from a National Cardiac Referral Centre in Africa. Cardiology 93: 11–18.AG AmoahC. Kallen2000Aetiology of heart failure as seen from a National Cardiac Referral Centre in Africa.Cardiology931118
  97. 97. Kimbally-Kaky G, Ekoba J, Nkoua JL, Bouramoue C (2000) [Endomyocardial fibrosis: report of 22 Congolese cases]. Ann Cardiol Angeiol (Paris) 49: 287–295.G. Kimbally-KakyJ. EkobaJL NkouaC. Bouramoue2000[Endomyocardial fibrosis: report of 22 Congolese cases].Ann Cardiol Angeiol (Paris)49287295
  98. 98. Turner PP, Manson-Bahr PE (1960) Endomyocardial fibrosis in Kenya and Tanganyika Africans. Br Heart J 22: 305–310.PP TurnerPE Manson-Bahr1960Endomyocardial fibrosis in Kenya and Tanganyika Africans.Br Heart J22305310
  99. 99. Kingue S, Dzudie A, Menanga A, Akono M, Ouankou M, et al. (2005) [A new look at adult chronic heart failure in Africa in the age of the Doppler echocardiography: experience of the medicine department at Yaounde General Hospital]. Ann Cardiol Angeiol (Paris) 54: 276–283.S. KingueA. DzudieA. MenangaM. AkonoM. Ouankou2005[A new look at adult chronic heart failure in Africa in the age of the Doppler echocardiography: experience of the medicine department at Yaounde General Hospital].Ann Cardiol Angeiol (Paris)54276283
  100. 100. Maru M (1993) The changing pattern of cardiovascular diseases in Ethiopia. East Afr Med J 70: 772–776.M. Maru1993The changing pattern of cardiovascular diseases in Ethiopia.East Afr Med J70772776
  101. 101. Sachs JD, Amoako KY, Aninat E, Diabre DCZ, Doryan E, et al. (2001) Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization. JD SachsKY AmoakoE. AninatDCZ DiabreE. Doryan2001Macroeconomics and health: investing in health for economic developmentGenevaWorld Health Organization
  102. 102. Hodes RM (1988) Pattern of heart disease in Ethiopia as seen in a cardiology referral clinic. Cardiology 75: 458–464.RM Hodes1988Pattern of heart disease in Ethiopia as seen in a cardiology referral clinic.Cardiology75458464
  103. 103. Harling D, Marsden P, Ridley D (1965) Some observations on the pattern of heart disease in the gambia. Trans R Soc Trop Med Hyg 59: 628–641.D. HarlingP. MarsdenD. Ridley1965Some observations on the pattern of heart disease in the gambia.Trans R Soc Trop Med Hyg59628641
  104. 104. Oyoo GO, Ogola EN (1999) Clinical and socio demographic aspects of congestive heart failure patients at Kenyatta National Hospital, Nairobi. East Afr Med J 76: 23–27.GO OyooEN Ogola1999Clinical and socio demographic aspects of congestive heart failure patients at Kenyatta National Hospital, Nairobi.East Afr Med J762327
  105. 105. Diallo B, Sanogo K, Diakite S, Diarra M, Toure M (2004) L'insuffisance cardiaque a l'hopital du point G. Mali Med 19: 15–17.B. DialloK. SanogoS. DiakiteM. DiarraM. Toure2004L'insuffisance cardiaque a l'hopital du point G.Mali Med191517
  106. 106. Thiam M (2002) L'insuffisance cardiaque en milieu cardiologique africain. Bull Soc Pathol Exot 96: 217–218.M. Thiam2002L'insuffisance cardiaque en milieu cardiologique africain.Bull Soc Pathol Exot96217218
  107. 107. Steenekamp JH, Simson IW, Theron W (1992) Cardiovascular causes of death at Tshepong Hospital in 1 year, 1989–1990. A necropsy study. S Afr Med J 81: 142–146.JH SteenekampIW SimsonW. Theron1992Cardiovascular causes of death at Tshepong Hospital in 1 year, 1989–1990. A necropsy study.S Afr Med J81142146
  108. 108. Richter J, Dengler A, Mohammed EG, Ali GM, Abdel-Rahim I, et al. (1990) Results of echocardiographic examinations in a regional hospital of central Sudan. Trans R Soc Trop Med Hyg 84: 749–752.J. RichterA. DenglerEG MohammedGM AliI. Abdel-Rahim1990Results of echocardiographic examinations in a regional hospital of central Sudan.Trans R Soc Trop Med Hyg84749752
  109. 109. Guimaraes A (1993) Natural history and current status in Brazil. In: Valiathan M, Somers K, Kartha CC, editors. Endomyocardial fibrosis. Delhi: Oxford University Press. pp. 37–54.A. Guimaraes1993Natural history and current status in Brazil.M. ValiathanK. SomersCC KarthaEndomyocardial fibrosisDelhiOxford University Press3754
  110. 110. Suarez J, Suarez C (1973) Fibrosis endomiocardica: estudio morfologico de 5 casos. Arch Inst Cardiol Mex 43: 58–67.J. SuarezC. Suarez1973Fibrosis endomiocardica: estudio morfologico de 5 casos.Arch Inst Cardiol Mex435867
  111. 111. Datta BN, Babu SK, Khattri HN, Bidwai PS, Wahi PL (1977) Endomyocardial fibrosis in Chandigarh area, India. A study of nine autopsies. Trop Geogr Med 29: 346–352.BN DattaSK BabuHN KhattriPS BidwaiPL Wahi1977Endomyocardial fibrosis in Chandigarh area, India. A study of nine autopsies.Trop Geogr Med29346352
  112. 112. Rashwan MA, Ayman M, Ashour S, Hassanin MM, Zeina AA (1995) Endomyocardial fibrosis in Egypt: an illustrated review. Br Heart J 73: 284–289.MA RashwanM. AymanS. AshourMM HassaninAA Zeina1995Endomyocardial fibrosis in Egypt: an illustrated review.Br Heart J73284289